Ref ID: 19258
Author:
M. A. Barron, K. Richardson, A. E. Hilts, M. E. Levi
Author address:
Univ. of Colorado Denver, Aurora, CO
Full conference title:
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy
Date: 10 September 2014
Abstract:
Background: Anidulafungin levels may be more predictable compared to caspofungin in patients with liver dysfunction and may be better tolerated; however, this has not been formally evaluated. We evaluated the safety and efficacy of anidulafungin compared to caspofungin as empiric or directed treatment of invasive fungal infections (IFI) in patients with hepatic insufficiency and/or liver transplantation. Methods: A retrospective chart review of 142 matched patients with hepatic dysfunction (Child’s Class B or C) or liver transplantation that received either anidulafungin or caspofungin from July 1, 2006 through January 31, 2010. Results: Thirty three subjects in each group were liver transplant recipients. The mean MELD score was similar in the anidulafungin versus caspofungin groups – 23 versus 24. Hepatitis C and alcohol were the most common causes of liver dysfunction. Risk factors for IFI and duration of antifungal therapy (7 days) were similar in both groups.C. albicans and C. glabrata were the most common yeast species isolated. Ten patients that were receiving caspofungin were changed to anidulafungin during treatment because of concerns about toxicity. Overall, 10 patients in the anidulafungin arm (14%) and 7
patients in the caspofungin arm (10%) had at least a fivefold
increase in their liver function tests compared to
baseline but these normalized by the completion of therapy
and were not thought to be due to antifungal therapy. The
median hospital stay was 27 days versus 32 days for
anidulafungin compared to caspofungin
respectively. Conclusions: Anidulafungin was well
tolerated in patients with liver dysfunction and/or liver
transplantation.
Abstract Number: NULL
Conference Year: 2013
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Felix Bongomin (UG)
2024
41
n/a
-
v
Khostelidi S1,2, Borzova Y2., Shadrivova O1, Desyatik E2., Karpishchenko S3 ., Charushin A.O4., Avdeenko Y2., Bogomolova T2., Ignatieva S2., Taraskina A.2, Burova S.A5., Vasylieva N.V.2
2024
40
n/a
-
v
Balogun O.J, Ajibola O.O.E., Oladele R.O., Fashanu T.A, Gangneux J.P., Denning D.W
2024
39
n/a
-
v
Su Chen, Ruoyu Li, Wei Chen, Zhe Wan, Wei Liu
2024
38
n/a
-
v
K.A. Marr,1,2 N. Permpalung,1 S. Rajack,1 K. Datta,1 D. Ostrander,1 J.F. Staab,1 K. Witwer,1 I. Baburina,2 D. Neitzey,2 P. X. Marques,2 R. Aerts,3 J. Maertens,3 D. Sheppard,4 J.R. Wingard,5 and S. X. Zhang,1
2024
37
n/a
-
v
Walshe. K, Dwyer. M and Doyle.S (IE)
2024
36
n/a
-
v
Jiří Houšť1, Radim Dobiáš2, Dominika Luptáková1, Andrea Palyzová1, Tomáš Pluháček1, Milan Navrátil3, David A. Stevens4, Rutuja H. Patil1, and Vladimír Havlíček1
2024
35
n/a
-
v
Mragnayani Pandey (IN), Immaculata Xess, Janya Sachdev, Neha Sharad, Sonakshi Gupta, Gagandeep Singh, Renu Kumari Yadav, Bhaskar Rana, Stephen Raj, M Nizam Ahmad, Neha Nityadarshini, Upendra Baitha, Manish Soneja, Shalimar, Bindu Prakash, Kapil Sikka, Purva Mathur, Viveka P Jyotsna, Rakesh Kumar, Naveet Wig, Ashutosh Biswas, Alok Thakar,
2024
34
n/a
-
v
Vladimir Havliecek1,2, R Dobias3,4, D Luptakova1, R Patil1,2, J Houst1,2, D Stevens5,6, M Petrik7, A Palyzova1, T Pluhacek1,2
2024
33
n/a
-
v
Sebastien Imbert (FR)
2024
32
n/a